A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

Bertrand Lell, Selidji Agnandji, Isabelle von Glasenapp et al. · 2009

Read A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon by Bertrand Lell, Selidji Agnandji, Isabelle von Glasenapp et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007611.txt.

Description

Bertrand Lell and colleagues published a randomized trial report in PLOS ONE in 2009 on the malaria vaccine candidate RTS,S in children in Gabon. RTS,S combines part of the malaria parasite's circumsporozoite protein with a hepatitis B surface protein. Its effect depends heavily on the adjuvant, the immune-boosting additive mixed with it. Two adjuvant systems, AS01 and AS02, were in development. The trial compared them head to head in children.

The trial assessed both safety and the immune responses each formulation produced. Head-to-head data like this decide which version advances. Children in malaria regions are the vaccine's true audience, so Gabonese children were the right test group. A formulation that is safe and strongly immunogenic there earns the next, larger trial. The study is one of the decision points in the long RTS,S story.

Catalog record

CREATORBertrand Lell, Selidji Agnandji, Isabelle von Glasenapp et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007611

Browse the full library · About the Tower of Babel